The Importance of Glutamine Concentration in Plasma for Cancer Related Fatigue
Completed
- Conditions
- G93.3Postviral fatigue syndrome
- Registration Number
- DRKS00003065
- Lead Sponsor
- Fresenius Kabi Deutschland GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients with solid tumor (e.g. colorectal carcinoma, stomach cancer, breast cancer, bronchial carcinoma, tumor in ENT region) and with causally determinded systemic therapy (radio- and/or chemo therapy).
Concentration of hemoglobin 9 g/dl or above
Patients without receiving blood transfusion or erythrocyte concentrate within last 4 weeks
Exclusion Criteria
Patients
- under 18 years
- not capable of understanding German language
- with psychological disorder
- with parenteral nutrition
- with active infection, requiring treatment
- with hematologic tumor (leukaemia)
- with glutamine treatment during the last 4 weeks
- with previous erythropoietin treatment
- Pregnant or breast feeding women
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary purpose of this trial is to evaluate whether Cancer Related Fatigue correlates with decreased Glutamine concentration. In- and out-patients who are treated with chemo- or radiotherapy at the Klinikum Großhadern will be included. There is only 1 visit destined.<br>In order to evaluate the severity of the fatigue the patient has to fill out the Cancer Fatigue Scale. The Scale consists of 15 items, classified in physical, affective and cognitive symptoms.<br>Fatigue is given in patiens with a value >=23.
- Secondary Outcome Measures
Name Time Method On visit date a blood sample will be taken from which Glutamine concentration will be determined. A value lower than 579 ± 9.2 µmol/l is defined as decreased. The Glutmamine value will be correlated with the Fatigue Score.